Switzerland’s Sandoz pivots to biosimilars, expects rapid mid-term growth
4 Articles
4 Articles
Switzerland’s Sandoz pivots to biosimilars, expects rapid mid-term growth
ZURICH, Sept 8 (Reuters) - Sandoz aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its focus from generics to bi...
The Sandoz Group has informed that it wants more than to double its net sales and increase its profitability over the next decade. The Swiss manufacturer of generic medicines has set on Tuesday the goal of more than doubling its net sales by 2035 compared to 2025, in addition to reaching a central Ebitda margin (lucer before interest, taxes, depreciation and depreciation) of more than 30% by 2035. Exclusive material for subscribers. To have full…
Sandoz presented new medium-term targets and a long-term growth strategy for the biosimilars business on its Investors' Day on Tuesday.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
